CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: Stimulation of allogeneic versus autologous T cells generates different types of effector cells

Blood

Volumn 93, Issue 6, 1999, Pages 1992-2002

  Buhmann, Raymund ^a   Nolte, Annette ^a   Westhaus, Doreen ^a   Emmerich, Bertold ^a   Hallek, Michael ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Genzentrum   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; TUMOR ANTIGEN;

ADULT; AGED; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNOTHERAPY; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLONAL ANERGY; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; FEMALE; HUMAN; IMMUNOPHENOTYPING; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; PRIORITY JOURNAL; REGULATORY MECHANISM; T LYMPHOCYTE ACTIVATION;

EID: 0033560068     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.6.1992.406k23_1992_2002     Document Type: Article

References (45)

1. Ribera JM, Vinolas N, Urbano IA, Gallart T, Montserrat E, Rozman C: "Spontaneous" complete remissions in chronic lymphocytic leukemia: Report of three cases and review of the literature. Blood Cells 12:471, 1987
2. Cantwell M, Hua T, Pappas J, Kipps TJ: Acquired CD40-ligand deficiency in chronic lymphocytic leukemia. Nat Med 3:984, 1997
3. Foa R, Lauria F, Lusso P, Giubellino MC, Fierro MT, Ferrando ML, Raspadori D, Matera L: Discrepancy between phenotypic and functional features of natural killer T-lymphocytes in B-cell chronic lymphocytic leukaemia. Br J Haematol 58:509, 1984
4. Platsoucas CD, Fernandes G, Gupta SL, Kempin S, Clarkson B, Good RA, Gupta S: Defective spontaneous and antibody-dependent cytotoxicity mediated by E-rosette-positive and E-rosette-negative cells in untreated patients with chronic lymphocytic leukemia: Augmentation by in vitro treatment with interferon. J Immunol 125:1216, 1980
5. Foa R, Fierro MT, Raspadori D, Bonferroni M, Cardona S, Guarini A, Tos AG, di Celle PF, Cesano A, Matera L: Lymphokine-activated killer (LAK) cell activity in B and T chronic lymphoid leukemia: Defective LAK generation and reduced susceptibility of the leukemic cells to allogeneic and autologous LAK effectors. Blood 76:1349, 1990
6. Cardoso AA, Schultze JL, Boussiotis VA, Freeman GJ, Seamon MJ, Laszlo S, Billet A, Sallan SE, Gribben JG, Nadler LM: Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen. Blood 88:41, 1996
7. Schultze JL, Cardoso AA, Freeman GJ, Seamon MJ, Daley J, Pinkus GS, Gribben JG, Nadler LM: Follicular lymphomas can be induced to present alloantigen efficiently: A conceptual model to improve their tumor immunogenicity. Proc Natl Acad Sci USA 92:8200, 1995
8. Caligaris CF, Gobbi M, Bofill M, Janossy G: Infrequent normal B lymphocytes express features of B-chronic lymphocytic leukemia. J Exp Med 155:623, 1982
9. Freedman AS, Boyd AW, Bieber FR, Daley J, Rosen K, Horowitz JC, Levy DN, Nadler LM: Normal cellular counterparts of B cell chronic lymphocytic leukemia. Blood 70:418, 1987
10. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2:52, 1996
11. Hsu FJ, Caspar CB, Czerwinski D, Kwak LW, Liles TM, Syrengelas A, Taidi LB, Levy R: Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - Long-term results of a clinical trial. Blood 89:3129, 1997
12. Nelson EL, Li X, Hsu FJ, Kwak LW, Levy R, Clayberger C, Krensky AM: Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkin's lymphoma. Blood 88:580, 1996
13. Ranheim EA, Cantwell MJ, Kipps TJ: Expression of CD27 and its ligand, CD70, on chronic lymphocytic leukemia B cells. Blood 85:3556, 1995
14. Schultze J, Nadler LM, Gribben JG: B7-mediated costimulation and the immune response. Blood Rev 10:111, 1996
15. Boussiotis VA, Freeman GJ, Gribben JG, Nadler LM: The role of B7-1/B7-2:CD28/CLTA-4 pathways in the prevention of anergy, induction of productive immunity and down-regulation of the immune response. Immunol Rev 153:5, 1996
16. Schwartz RH: A cell culture model for T lymphocyte clonal anergy. Science 248:1349, 1990
17. Schwartz RH: Costimulation of T lymphocytes: The role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 71:1065, 1992
18. Banchereau J, Bazan F, Blanchard D, Briere F, Galizzi JP, van KC, Liu YJ, Roussel F, Saeland S: The CD40 antigen and its ligand. Annu Rev Immunol 12:881, 1994
19. Dighiero G, Travade P, Chevret S, Fenaux P, Chastang C, Binet JL: B-cell chronic lymphocytic leukemia: Present status and future directions. French Cooperative Group on CLL. Blood 78:1901, 1991
20. Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, Vaugier G, Potron G, Colona P, Oberling F, Thomas M, Tchernia G, Jacquillat C, Boivin P, Lesty C, Duault MT, Monconduit M, Belabbes S, Gremy F: A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48:198, 1981
21. Urashima M, Chauhan D, Uchiyama H, Freeman GJ, Anderson KC: CD40 ligand triggered interleukin-6 secretion in multiple myeloma. Blood 85:1903, 1995
22. Brunner KT, Mauel J, Cerottini JC, Chapuis B: Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. Immunology 14:181, 1968
23. Boussiotis VA, Freeman GJ, Gribben JG, Nadler LM: The critical role of CD28 signalling in the prevention of human T-cell anergy. Res Immunol 146:140, 1995
24. Gimmi CD, Freeman GJ, Gribben JG, Gray G, Nadler LM: Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci USA 90:6586, 1993
25. Crawford DH, Catovsky D: In vitro activation of leukaemic B cells by interleukin-4 and antibodies to CD40. Immunology 80:40, 1993
26. Fluckiger AC, Rossi JF, Bussel A, Bryon P, Banchereau J, Defrance T: Responsiveness of chronic lymphocytic leukemia B cells activated via surface Igs or CD40 to B-cell tropic factors. Blood 80:3173, 1992
27. Van den Hove LE, Van Gool SW, Vandenberghe P, Bakkus M, Thielemans K, Boogaerts MA, Ceuppens JL: CD40 triggering of chronic lymphocytic leukemia B cells results in efficient alloantigen presentation and cytotoxic T lymphocyte induction by up-regulation of CD80 and CD86 costimulatory molecules. Leukemia 11:572, 1997
28. + T cells. Eur J Immunol 27:598, 1997
29. Freeman GJ BV, Anumanthan A, Bernstein GM, Ke XY, Rennert PD, Gray GS, Gribben JG, Nadler LM: B7-1 and B7-2 do not deliver identical costimulatory signals since B7-2 but not B7-1 preferntially costimulates the initial production of IL-4. Immunity 2:523, 1995
30. van Dijk AM, Otten HG, Vercauteren SM, Kessler FL, de Boer M, Verdonck LF, de Gast GC: Human B7-1 is more efficient than B7-2 in providing co-stimulation for alloantigen-specific T cells. Eur J Immunol 26:2275, 1996
31. Schultze JL, Seamon MJ, Michalak S, Gribben JG, Nadler LM: Autologous tumor infiltrating T cells cytotoxic for follicular lymphoma cells can be expanded in vitro. Blood 89:3806, 1997
32. Cardoso AA, Seamon MJ, Afonso HM, Ghia P, Boussiotis VA, Freeman GJ, Gribben JG, Sallan SE, Nadler LM: Ex vivo generation of human anti-pre-B leukemia-specific autologous cytolytic T cells. Blood 90:549, 1997
33. + T lymphocytes. J Immunol 152:1523, 1994
34. King CA, Wills MR, Hamblin TJ, Stevenson FK: Idiotypic IgM on a B-cell surface requires processing for recognition by anti-idiotypic T cells. Cell Immunol 147:411, 1993
35. + T cells and immunosurveillance of B-cell tumors. Proc Natl Acad Sci USA 91:5700, 1994
36. Lauritzsen GF, Weiss S, Bogen B: Anti-tumour activity of idiotype-specific, MHC-restricted Th1 and Th2 clones in vitro and in vivo. Scand J Immunol 37:77, 1993
37. Kato K, Cantwell MJ, Sharma S, Kipps TJ: Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest 101:1133, 1998
38. Garrone P, Neidhardt EM, Garcia E, Galibert L, van Kooten C, Banchereau J: Fas ligation induces apoptosis of CD40-activated human B lymphocytes. J Exp Med 182:1265, 1995
39. Schattner EJ, Elkon KB, Yoo DH, Tumang J, Krammer PH, Crow MK, Friedman SM: CD40 ligation induces Apo-1/Fas expression on human B lymphocytes and facilitates apoptosis through the Apo-1/ Fas pathway. J Exp Med 182:1557, 1995
40. Schattner E, Friedman SM: Fas expression and apoptosis in human B cells. Immunol Res 15:246, 1996
41. Jaiswal AI, Dubey C, Swain SL, Croft M: Regulation of CD40 ligand expression on naive CD4 T cells: A role for TCR but not co-stimulatory signals. Int Immunol 8:275, 1996
42. Jaiswal AI, Croft M: CD40 ligand induction on T cell subsets by peptide-presenting B cells: Implications for development of the primary T and B cell response. J Immunol 159:2282, 1997
43. Cantwell MJ, Hua T, Pappas J, Kipps TJ: Acquired CD40-ligand deficiency in chronic lymphocytic leukemia. Nat Med 3:984, 1997
44. Dubey C, Croft M, Swain SL: Naive and effector CD4 T cells differ in their requirements for T cell receptor versus costimulatory signals. J Immunol 157:3280, 1996
45. + T lymphocytes from TCR transgenic mice. J Immunol 152:5220, 1994